Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi

dc.creatorQueiroz, Aline Maria Vasconcelos
dc.creatorYanshina, Yulia Aleksandrovna
dc.creatorRodrigues, Emily Thays da Silva
dc.creatorSantos, Fred Luciano Neves
dc.creatorCeledon, Paola Alejandra Fiorani
dc.creatorMaheshwari, Sweta
dc.creatorGabelli, Sandra Beatriz
dc.creatorRubio, Carla Stephanie Peucelle
dc.creatorDurana, Aritz
dc.creatorGuérin, Diego M. A.
dc.creatorSilva, Marcelo Sousa
dc.date2021-07-21T14:02:32Z
dc.date2021-07-21T14:02:32Z
dc.date2021
dc.date.accessioned2023-09-26T20:45:13Z
dc.date.available2023-09-26T20:45:13Z
dc.identifierQUEIROZ, Aline Maria Vasconcelos et al. Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi. Vaccine, v. 39, n. 33, p. 4723-4732, 30 July 2021.
dc.identifier0264-410X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/48330
dc.identifier10.1016/j.vaccine.2021.05.039
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8863259
dc.descriptionConsejo Superior de Investigaciones Científicas (grant number COOPB20503 - CSIC, Spain)
dc.descriptionGlobal Health and Tropical Medicine [grant number GHTM-UID/multi/04413/2013]
dc.descriptionMinisterio de Ciencia e Innovación [BFU2012-36241]
dc.descriptionGrupos Investigación UPV/EHU 2018 [GIU18/172]
dc.descriptionGobierno Vasco [Elkartek KK-2017/00008]
dc.descriptionPrograma de empresas Innovadoras A1 2020 EKINZAILE
dc.descriptionThe Basque Country, Spain
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brasil)
dc.descriptionBackground: The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the form of a vaccine preparation. Virus-like particles (VLPs) are structures analogous to viral capsids composed essentially of structural proteins and are widely used in vaccination protocols because of their immunostimulatory properties. In this context, the objective of this study was to use strategies in a murine immunization model to characterize the immunostimulatory capacity of VLPs from Triatoma virus (TrV-VLPs), analysed in the presence or absence of the aluminium vaccine adjuvant. In parallel, to characterize the immunogenic behaviour of four T. cruzi chimeric recombinant proteins (mix-IBMP) associated with TrV-VLPs or aluminium vaccine adjuvant. Method: We immunized BALB/c mice once or twice, depending on the strategy, and collected serum samples at 15, 30 and 45 days after the immunization. Subsequently, serum samples from animals immunized with TrV-VLPs were used to determine total IgG, IgG1, IgG2a, IgG2b and IgG3 anti-TrV-VLPs by enzyme-linked immunosorbent assay (ELISA). Results: Data obtained demonstrate the ability of TrV-VLPs to preferably induce IgG2b and IgG3 type antibodies in the absence of aluminium adjuvant. In fact, the use of aluminium did not interfere with the total IgG profile of anti-TrV-VLPs. Interestingly, mix-IBMP had a better profile of total IgG, IgG1 and IgG3 subclasses when mixed with TrV-VLPs. Conclusion: In conclusion, these results suggest the potential of TrV-VLPs as a vaccine adjuvant and the use of T. cruzi chimeric antigens as a rational strategy for the development of vaccines against the experimental model of Chagas disease.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsrestricted access
dc.subjectVírus
dc.subjectDoença de Chagas
dc.subjectTrypanosoma cruzi
dc.subjectVacinação
dc.subjectImunização
dc.subjectTriatoma
dc.subjectVirus-like particles (VLPs)
dc.subjectChagas disease
dc.subjectTrypanosoma cruzi
dc.subjectAdjuvant
dc.subjectHumoral immune response
dc.subjectTriatoma virus
dc.titleAntibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi
dc.typeArticle


Este ítem pertenece a la siguiente institución